UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PSTSAN RAFAEL, Calif., Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Score ...

BioMarin Pharmaceutical (BMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a c ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive est ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical (BMRN) reported adjusted earnings per share of 91 cents in third-quarter 2024, beating the Zacks Consensus Estimate of 78 cents. Quarterly earnings rose 98% year over year, driven by higher sales, partially offset by rising operating expenses. Total revenues were $746 million in the reported quarter, up 28% year over year on a reported basis and 32% on a constant-currency basis. Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consensus Estimate of $707 million. ...

财务数据和关键指标变化 - 公司第三季度2024年总收入达到7.46亿美元，同比增长28% [5][19] - 非GAAP稀释每股收益（EPS）为0.91美元，较2023年同期几乎翻倍 [25] - GAAP稀释每股收益（EPS）为0.55美元，同比增长162% [25] - 经营现金流为2.21亿美元，同比增长63% [26] 各条业务线数据和关键指标变化 - VOXZOGO收入为1.9亿美元，同比增长54% [19][25] - 酶疗法组合收入为5.09亿美元，同比增长27% [20] - NAGLAZYME收入增长21%，PALANZIQ收入增长15% [21][22] 各个市场数据和关键指标变化 - VOXZOGO在美国和新市场的渗透率显著提高，推动了新患者的增加 [8][33] - 全球酶疗法组合在第三季度表现良好，预计未来将继续增长 [13][22] 公司战略和发展方向和行业竞争 - 公司实施新的企业战略，专注于创新、增长和价值承诺 [6][30] - 设立新的业务单元以提高效率和收入增长 [6] - 预计到2027年实现约40%的非GAAP经营利润率 [15] 管理层对经营环境和未来前景的评论 - 管理层对未来的市场前景持乐观态度，预计将继续实现强劲的商业表现 [22][30] - 公司重申了长期收入目标，预计到2027年总收入将达到约40亿美元 [15] 其他重要信息 - 公司在第三季度成功偿还4.95亿美元的可转换债务，未发行新债务 [27] - 预计2024年全年收入指导范围为27.9亿至28.25亿美元 [22][28] 问答环节所有的提问和回答 问题: VOXZOGO的增长情况 - VOXZOGO在第三年继续增长，主要新患者来自0至5岁年龄段 [53][54] 问题: BMN 333的开发策略 - BMN 333预计将在2025年进入临床试验，目标是提高药物的半衰期和生物利用度 [59][60] 问题: NAGLAZYME的增长原因 - NAGLAZYME在市场上表现良好，主要得益于患者的持续需求和公司新的市场策略 [120]

BioMarin Pharmaceutical (BMRN) reported $745.74 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 28.3%. EPS of $0.91 for the same period compares to $0.46 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $706.95 million, representing a surprise of +5.49%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.78. While investors scrutinize revenue and earnings changes year-over-year and how they ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.57 per share when it actually produced earnings of $0.96, delivering a surprise of 68.42%.Over the l ...

业绩总结 - BioMarin第三季度2024年总收入为7.46亿美元，同比增长28%[11] - BioMarin第三季度2024年非GAAP稀释每股收益为0.91美元，同比增长98%[11] - BioMarin第三季度2024年非GAAP运营利润率为27.7%，较去年同期提升11.5个百分点[11] - 2024年第三季度GAAP运营收入为114百万美元，占GAAP总收入的15.3%[18] - 2024年第三季度非GAAP运营收入为207百万美元，占GAAP总收入的27.7%[18] - 2024年第三季度GAAP稀释每股收益为0.55美元，2023年为0.21美元[19] - 2024年第三季度非GAAP稀释每股收益为0.91美元，2023年为0.46美元[19] - 2024年九个月的GAAP运营收入为323百万美元，占GAAP总收入的15.3%[18] 用户数据 - VOXZOGO在第三季度的收入增长54%，主要受益于各地区患者数量的增加[7] - 酶疗法在第三季度的收入增长27%，大多数产品实现了两位数的增长[7] 未来展望 - BioMarin将2024年总收入指导上调至27.9亿至28.25亿美元[14] - BioMarin预计2024年非GAAP运营利润率指导为26.5%至27.5%[14] - BioMarin预计2024年非GAAP稀释每股收益指导为3.25至3.35美元[14] - BioMarin预计到2027年实现约40%的非GAAP运营利润率[15] 市场扩张 - BioMarin计划到2027年在20多个国家扩大VOXZOGO的可及性[7] 费用和支出 - 2024年第三季度的股权激励费用为43百万美元，占GAAP总收入的5.7%[18] - 2024年第三季度的重组和裁员费用为45百万美元，占GAAP总收入的6.0%[18] - 2024年第三季度的无形资产摊销费用为5百万美元，占GAAP总收入的0.7%[18] 股本信息 - 2024年第三季度加权平均稀释流通股数为197.1百万股，2023年为191.2百万股[20] - 2024年第三季度的调整后非GAAP加权平均稀释流通股数为197.1百万股，2023年为199.6百万股[20]